VRXA

Veraxa Biotech AG
CAPPED RATING

Veraxa Biotech AG (VRXA) is rated D+ (1.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B-); its weakest is Value (F). The rating has held at D+ for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
1.8 / 5.0
D+
Value
F
Factor Score 0.0 / 5.0
Growth
C+
Factor Score 2.5 / 5.0
Profitability
B-
Factor Score 2.9 / 5.0
Momentum
D-
Factor Score 1.0 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio N/A
EV / EBITDA N/A
Rev Growth YoY N/A
Gross Margin 66.0%
Price Return 3M -40.3%
Price Return 12M -89.4%
Catalyst Signal 0.00
Market Cap $157.0M
TTM Revenue $23.4K
Price / Sales 6.7K
ROE N/M

Historical Factor Score Progression

Held D+ for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-15 F (0.0) C+ (2.5) B- (2.9) D- (1.0) C+ (2.6) D+ (1.8)
2026-11-08 F (0.0) C+ (2.5) B- (2.9) D- (0.8) C+ (2.6) D+ (1.8)
2026-11-01 F (0.0) C+ (2.5) B- (2.9) D- (1.0) C+ (2.7) D+ (1.8)
2026-10-25 F (0.0) C+ (2.5) B- (2.9) F (0.7) C+ (2.6) D+ (1.7)
2026-10-18 F (0.0) C+ (2.5) B- (2.9) D- (0.8) C+ (2.6) D+ (1.8)
Page 1 of 3